<?xml version='1.0' encoding='utf-8'?>
<document id="28332824"><sentence text="Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease."><entity charOffset="19-33" id="DDI-PubMed.28332824.s1.e0" text="Benzothiazoles" /><entity charOffset="38-50" id="DDI-PubMed.28332824.s1.e1" text="Benzoxazoles" /><pair ddi="false" e1="DDI-PubMed.28332824.s1.e0" e2="DDI-PubMed.28332824.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28332824.s1.e0" e2="DDI-PubMed.28332824.s1.e1" /></sentence><sentence text="To develop novel, selective, and reversible MAO-B inhibitors for safer treatment of Parkinson's disease, benzothiazole and benzoxazole derivatives with indole moiety were designed and synthesized"><entity charOffset="105-118" id="DDI-PubMed.28332824.s2.e0" text="benzothiazole" /><entity charOffset="123-134" id="DDI-PubMed.28332824.s2.e1" text="benzoxazole" /><entity charOffset="152-158" id="DDI-PubMed.28332824.s2.e2" text="indole" /><pair ddi="false" e1="DDI-PubMed.28332824.s2.e0" e2="DDI-PubMed.28332824.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28332824.s2.e0" e2="DDI-PubMed.28332824.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28332824.s2.e0" e2="DDI-PubMed.28332824.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28332824.s2.e1" e2="DDI-PubMed.28332824.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28332824.s2.e1" e2="DDI-PubMed.28332824.s2.e2" /></sentence><sentence text=" Most of the synthesized compounds showed inhibitory activities against MAO-B and selectivity over MAO-A" /><sentence text=" The most active compound was compound 5b, 6-fluoro-2-(1-methyl-1H-indol-5-yl)benzo[d]thiazole with an IC50 value of 28 nM with no apparent effect on MAO-A activity at 10 Î¼M"><entity charOffset="39-94" id="DDI-PubMed.28332824.s4.e0" text="5b, 6-fluoro-2-(1-methyl-1H-indol-5-yl)benzo[d]thiazole" /></sentence><sentence text=" Based on the reversibility assay, compound 5b turned out to be fully reversible with over 95% of recovery of enzyme activity after washout of the compound" /><sentence text=" Compound 5b showed a reasonable stability in human liver microsomes and did not affect the activities of CYP isozymes, suggesting an absence of high-risk drug-drug interaction" /><sentence text=" In an in vivo MPTP-induced animal model of Parkinson's disease, oral administration of compound 5b showed neuroprotection of nigrostriatal dopaminergic neurons as revealed by tyrosine hydroxylase staining and prevention of MPTP-induced parkinsonism as revealed by motor behavioral assay of vertical grid test"><entity charOffset="176-184" id="DDI-PubMed.28332824.s7.e0" text="tyrosine" /></sentence><sentence text=" In summary, the novel, reversible, and selective MAO-B inhibitor compound 5b was synthesized and characterized" /><sentence text=" We propose compound 5b as an effective therapeutic compound for relieving parkinsonism" /><sentence text="" /></document>